Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
By John R. Geddes, N. Freemantle, P. Harrison, P. Bebbington. British medical journal, 2000
1,034 citations recorded by the source corpus.
Subfields: Clinical Psychology, Psychiatry and Mental health, Philosophy
View Paper: https://www.semanticscholar.org/paper/25baabd1aaec4b4d05f243684523e93c79026b09
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Clinical Psychology
In Psychiatry and Mental health
In Philosophy
Citations in the corpus
- Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. (2005, neutral): “Obsessive–compulsive disorder 10 (3) 22 (7) 21 (6) 12 (5) 8 (4) 73 (5)”
- Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy (2002, background): “A recent meta-analysis has suggested that the benefit even of the new atypical antipsychotics is less than previously thought (Geddes et al. 2000).”
- Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. (2002, background): “(30) concluded that the primary benefit of atypical antipsychotics was in reducing side effects.”
- Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). (2006, methodology): “FGA arm (n = 118) Chlorpromazine 8 4 250 (200-300) Droperidol 1 0 0 Flupentixol 1 3 4 (2-6) Flupentixol decanoate 2 8 142 fortnightly (40 mo to 250 wk) Fluphenazine decanoate 3 2 50 fortnightly Haloperidol 8 2 22.”